Flow cytometry supervised analysis showed no significant difference in the expression of maturity markers (CD16, CD10, CD33), activation markers (CD11b, CD66b, and CD62L), metabolic markers (LOX1, GLUT1) nor immunosuppression and/or exhaustion markers (PD1, PD-L1) between whole blood neutrophils from healthy donors and stable CF patients (Figure 1B). This evidence concerns the gene SLC2A1 and cystic fibrosis.